Pfizer drug enters late-stage trial
A new lung-cancer drug jointly developed by Pfizer Inc. and Merck has enrolled its first patient for a late-stage trial.
The study will look at the effectiveness and safety of experimental treatment avelumab compared with the standard treatment docetaxel in patients with late-stage lung cancer.
About 650 patients are expected to participate in the so-called JAVELIN study at nearly 300 sites in more then 30 countries. Overall survival rates will be the primary focus of the study.
Mace Rothenberg, chief medical officer for Pfizer Oncology, said the study "underscores our commitment to accelerating the development of medications for patients with cancer."
Comment threads are monitored for 48 hours after publication and then closed.
